rena Pharmaceuticals passed the first test of its drug development comeback strategy by delivering positive results from a mid-stage study targeting pulmonary arterial hypertension (PAH), a rare and debilitating disease caused by high blood pressure in the arteries that connect the heart to the lungs.

In the study of 61 PAH patients already on standard background therapy, Arena’s experimental drug ralinepag reduced pulmonary vascular pressure by 30 percent compared to a placebo. The difference was statistically significant, achieving the primary endpoint of the study. Pulmonary vascular pressure measures the pressure inside the arteries connecting the lungs with the heart.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy